Early diagnosis and treatment of PAH improve survival

Robyn Kalda
Jan 19
1 min read

This study examined the causes of delayed diagnosis (diagnosis after approximately 22 months) of pulmonary arterial hypertension (PAH) and whether an earlier diagnosis (within six months) leads to better outcomes. They identified several factors associated with delayed diagnosis and found that earlier diagnosis and treatment were associated with better survival.

Read the Pulmonary Circulation article

Recent Posts

Sotatercept and cardiopulmonary comorbidities

This study from one clinic examined how well sotatercept worked in real-world patients with pulmonary arterial hypertension (PAH) who also had other heart or lung conditions, such as coronary artery d

Start up: Supporting PAH patients beginning prostanoids

This study looked at a French support program designed to help people with pulmonary arterial hypertension (PAH) start and adjust their dose of selexipag. Nurses called patients three days after patie

Sotatercept vs. selexipag in severe PAH

Researchers used AI to indirectly compare data from three randomized controlled trials looking at sotatercept or selexipag in pulmonary arterial hypertension (PAH). Their findings suggest that sotater

Comments